Cambridge Trust’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $25.2M | Buy |
32,440
+21,510
| +197% | +$15.3M | 0.95% | 35 |
|
|
2023
Q4 | $6.37M | Buy |
10,930
+78
| +0.7% | +$45.5K | 0.27% | 84 |
|
|
2023
Q3 | $5.83M | Sell |
10,852
-71
| -0.7% | -$36.6K | 0.27% | 79 |
|
|
2023
Q2 | $5.12M | Buy |
10,923
+88
| +0.8% | +$36.9K | 0.23% | 82 |
|
|
2023
Q1 | $3.72M | Sell |
10,835
-98
| -0.9% | -$33.1K | 0.18% | 89 |
|
|
2022
Q4 | $4M | Buy |
10,933
+371
| +4% | +$132K | 0.18% | 90 |
|
|
2022
Q3 | $3.42M | Buy |
10,562
+200
| +2% | +$63.4K | 0.16% | 97 |
|
|
2022
Q2 | $3.36M | Buy |
10,362
+652
| +7% | +$196K | 0.15% | 101 |
|
|
2022
Q1 | $2.78M | Sell |
9,710
-822
| -8% | -$212K | 0.1% | 115 |
|
|
2021
Q4 | $2.91M | Buy |
10,532
+3,152
| +43% | +$799K | 0.09% | 114 |
|
|
2021
Q3 | $1.71M | Sell |
7,380
-169
| -2% | -$41.7K | 0.06% | 116 |
|
|
2021
Q2 | $1.73M | Buy |
7,549
+282
| +4% | +$56.6K | 0.07% | 117 |
|
|
2021
Q1 | $1.36M | Sell |
7,267
-194
| -3% | -$37.9K | 0.06% | 123 |
|
|
2020
Q4 | $1.26M | Sell |
7,461
-900
| -11% | -$134K | 0.06% | 108 |
|
|
2020
Q3 | $1.24M | Sell |
8,361
-112
| -1% | -$17.3K | 0.06% | 108 |
|
|
2020
Q2 | $1.31M | Sell |
8,473
-442
| -5% | -$67.8K | 0.07% | 106 |
|
|
2020
Q1 | $1.24M | Sell |
8,915
-645
| -7% | -$88.6K | 0.08% | 103 |
|
|
2019
Q4 | $1.26M | Sell |
9,560
-105
| -1% | -$12.2K | 0.07% | 126 |
|
|
2019
Q3 | $1.08M | Sell |
9,665
-145
| -1% | -$16.1K | 0.06% | 130 |
|
|
2019
Q2 | $1.09M | Sell |
9,810
-1,998
| -17% | -$235K | 0.06% | 127 |
|
|
2019
Q1 | $1.53M | Sell |
11,808
-232
| -2% | -$28.2K | 0.09% | 111 |
|
|
2018
Q4 | $1.39M | Sell |
12,040
-602
| -5% | -$67.2K | 0.1% | 112 |
|
|
2018
Q3 | $1.36M | Buy |
12,642
+740
| +6% | +$74K | 0.08% | 115 |
|
|
2018
Q2 | $1.02M | Buy |
11,902
+578
| +5% | +$47.5K | 0.06% | 133 |
|
|
2018
Q1 | $876K | Buy |
11,324
+4,073
| +56% | +$328K | 0.06% | 142 |
|
|
2017
Q4 | $612K | Sell |
7,251
-118
| -2% | -$10K | 0.04% | 167 |
|
|
2017
Q3 | $631K | Buy |
7,369
+2,000
| +37% | +$164K | 0.04% | 159 |
|
|
2017
Q2 | $442K | Sell |
5,369
-35
| -0.6% | -$2.85K | 0.03% | 176 |
|
|
2017
Q1 | $454K | Sell |
5,404
-386
| -7% | -$30.9K | 0.03% | 188 |
|
|
2016
Q4 | $426K | Buy |
5,790
+11
| +0.2% | +$819 | 0.03% | 191 |
|
|
2016
Q3 | $464K | Sell |
5,779
-149
| -3% | -$11.9K | 0.03% | 180 |
|
|
2016
Q2 | $466K | Sell |
5,928
-354
| -6% | -$26.7K | 0.04% | 173 |
|
|
2016
Q1 | $452K | Buy |
6,282
+615
| +11% | +$46.5K | 0.04% | 157 |
|
|
2015
Q4 | $477K | Buy |
5,667
+31
| +0.6% | +$2.57K | 0.04% | 146 |
|
|
2015
Q3 | $472K | Sell |
5,636
-40
| -0.7% | -$3.38K | 0.04% | 147 |
|
|
2015
Q2 | $474K | Buy |
5,676
+1,887
| +50% | +$144K | 0.04% | 145 |
|
|
2015
Q1 | $275K | Buy |
3,789
+190
| +5% | +$13.5K | 0.02% | 187 |
|
|
2014
Q4 | $248K | Hold |
3,599
| – | – | 0.02% | 191 |
|
|
2014
Q3 | $233K | Sell |
3,599
-100
| -3% | -$6.33K | 0.02% | 186 |
|
|
2014
Q2 | $230K | Hold |
3,699
| – | – | 0.02% | 187 |
|
|
2014
Q1 | $217K | Buy |
+3,699
| New | +$206K | 0.02% | 192 |
|
|
2013
Q4 | – | Sell |
-4,861
| Closed | -$244K | – | 196 |
|
|
2013
Q3 | $244K | Buy |
+4,861
| New | +$254K | 0.02% | 163 |
|
Other funds holding LLY
Cambridge Trust's LLY Position: Q1 2024 in Review
Cambridge Trust increased its Eli Lilly (LLY) stake by 197% in Q1 2024, buying an estimated $15.3M and bringing the position to 32,440 shares worth $25.2M. The position accounts for 0.95% of the portfolio, ranked #35.
Cambridge Trust first reported a position in LLY in Q3 2013 and has held it in 42 quarters since. 3,461 funds tracked by Wall St. Rank hold LLY as of Q1 2024.
- Cambridge Trust held 32,440 shares of Eli Lilly worth $25.2M as of Q1 2024.
- Cambridge Trust bought 21,510 Eli Lilly shares in Q1 2024, an estimated $15.3M.
- Eli Lilly made up 0.95% of Cambridge Trust's portfolio in Q1 2024, its #35 holding.
- Cambridge Trust first reported a position in Eli Lilly in Q3 2013 and has held it in 42 quarters since.
- 3,461 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2024.
Based on Cambridge Trust's 13F filing for Q1 2024, filed 30 May 2024.